Top 50 Medical VC Funds & Investors in Finland (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Business Finland
VC Fund
|
9 | Finland, United States, Sweden | Grant, Seed, Debt Financing | Software, SaaS, Biotechnology | $50k–$10M |
|
Finnvera Venture Capital
VC Fund
|
7 | Finland, United States, Chile | Seed, Series A | Software, Health Care, Manufacturing | $250k–$23M |
|
Lifeline Ventures
VC Fund
|
7 | Finland, United States, United Kingdom | Seed, Series A, Venture - Series Unknown | Software, Health Care, Artificial Intelligence | $430k–$22M |
|
Voima Ventures
VC Fund
|
6 | Finland, Sweden, Norway | Seed, Pre-Seed, Series A | Biotechnology, Health Care, Artificial Intelligence | $464k–$30M |
|
Innovestor
VC Fund
|
5 | Finland, Sweden, Denmark | Seed, Venture - Series Unknown, Pre-Seed | Software, Health Care, Information Technology | $204k–$5.1M |
|
Icebreaker.vc
VC Fund
|
4 | Finland, Sweden, Estonia | Pre-Seed, Seed, Series A | Software, Information Technology, Artificial Intelligence | $110k–$25M |
|
Maki.vc
VC Fund
|
4 | Finland, Norway, Denmark | Seed, Series A, Pre-Seed | Software, E-Commerce, Information Technology | $578k–$37M |
|
Butterfly Ventures
VC Fund
|
3 | Finland, Sweden, Norway | Seed, Pre-Seed | Software, Health Care, Information Technology | $110k–$4.3M |
|
StartUp Health
VC Fund
|
3 | United States, Canada, United Kingdom | Seed, Venture - Series Unknown, Pre-Seed | Health Care, Medical, Wellness | $20k–$15M |
|
Novo Holdings
VC Fund
|
3 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
Karolinska
VC Fund
|
3 | Sweden, Denmark, United States | Venture - Series Unknown, Seed | Biotechnology, Health Care, Pharmaceutical | $3.2M–$10M |
|
M Ventures
VC Fund
|
3 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Novartis Venture Fund
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
Nordic Science Investments
VC Fund
|
3 | Finland, Sweden, United States | Seed, Pre-Seed, Series A | Biotechnology, Medical, Health Diagnostics | $373k–$34M |
|
Reaktor Ventures
VC Fund
|
3 | Finland, Germany, United States | Seed, Pre-Seed, Series A | Software, Internet, E-Commerce | $137k–$6.8M |
|
Springvest
VC Fund
|
3 | Finland | Series A, Venture - Series Unknown, Seed | Biotechnology, Health Care, Medical | $1.6M–$53M |
|
Tesi
VC Fund
|
3 | Finland, United States, Switzerland | Series A, Series B | Software, Manufacturing, Information Technology | $2.4M–$46M |
|
Sandwater
VC Fund
|
2 | Norway, Germany, Finland | Series A, Venture - Series Unknown, Series B | Manufacturing, Medical, AgTech | $4.7M–$35M |
|
Vesalius Biocapital Partners
VC Fund
|
2 | Belgium, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $3.9M–$100M |
|
Nuard Ventures
VC Fund
|
2 | Finland, Germany, United States | Seed, Angel, Pre-Seed | IaaS, Video, Gaming | $159k–$680k |
|
Metsola Ventures
VC Fund
|
2 | Finland | Series A, Pre-Seed | Medical, mHealth, Automotive | $2.2M–$5.4M |
|
Inventure
VC Fund
|
2 | Finland, Sweden, United States | Seed, Series A, Series B | Software, Information Technology, Artificial Intelligence | $549k–$25M |
|
Samsung Venture Investment
VC Fund
|
2 | South Korea, United States, India | Series A, Series B, Seed | Information Technology, Artificial Intelligence, Software | $83k–$25M |
|
University of Helsinki
VC Fund
|
2 | Finland, Luxembourg, United States | Seed, Series A, Pre-Seed | Medical, Health Care, Biotechnology | $54k–$34M |
|
Cascara Ventures
VC Fund
|
2 | Germany, Finland, The Netherlands | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $2M–$7.9M |
|
Indaco Venture Partners
VC Fund
|
1 | Italy, United Kingdom, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $3.5M–$110M |
|
Korpun Siemen
VC Fund
|
1 | Finland | Seed, Venture - Series Unknown, Angel | Software, Marketing, Information Technology | $480k–$1.3M |
|
Lednil
VC Fund
|
1 | Finland | Series A | Medical, Commercial, Health Care | |
|
Metaplanet
VC Fund
|
1 | United States, United Kingdom, Estonia | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $1.7M–$62M |
|
Force 10 Partners
VC Fund
|
1 | Finland | Seed | Medical, Health Care, Biotechnology | |
|
MVM Life Science Partners
VC Fund
|
1 | United States, United Kingdom, Switzerland | Series B, Series C | Health Care, Medical, Biotechnology | $7M–$45M |
|
Cor Group
VC Fund
|
1 | Finland | Seed, Pre-Seed, Series A | Health Care, Medical, Biotechnology | $2.3M–$8.7M |
|
CDP Venture Capital
VC Fund
|
1 | Italy, United States, United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $483k–$23M |
|
Ananda Impact Ventures
VC Fund
|
1 | Germany, United Kingdom, Finland | Seed, Series A, Series B | Health Care, Software, Information Technology | $1.6M–$53M |
|
Mérieux Equity Partners
VC Fund
|
1 | France, United States, Belgium | Series A, Private Equity, Series B | Health Care, Biotechnology, Medical Device | $5.7M–$150M |
|
Capricorn Partners
VC Fund
|
1 | Belgium, The Netherlands, United States | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$45M |
|
ZEISS Ventures
VC Fund
|
1 | Germany, United Kingdom | Series A | Health Care, Semiconductor, Medical Device | $5.2M–$23M |
|
Athensmed
VC Fund
|
1 | Finland, Switzerland | Seed, Series A | Health Care, Health Diagnostics, Medical | $1.1M–$4.3M |
|
Hadean Ventures
VC Fund
|
1 | Sweden, Norway, Austria | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Medical | $2M–$79M |
|
Debiopharm Innovation Fund
VC Fund
|
1 | United States, Switzerland, France | Series A, Seed, Pre-Seed | Health Care, Biotechnology, Software | $317k–$25M |
|
Nordea
VC Fund
|
1 | Finland, Sweden, Norway | Debt Financing, Seed | FinTech, Financial Services, Banking | |
|
Torrey Pines Investment
VC Fund
|
1 | United States, Russian Federation, The Netherlands | Seed, Pre-Seed | Biotechnology, Health Care, Pharmaceutical | $3M–$3.1M |
|
Sunstone Life Science Ventures
VC Fund
|
1 | Denmark, Sweden, Switzerland | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$61M |
|
SHS Capital
VC Fund
|
1 | Germany, Switzerland, France | Venture - Series Unknown, Series B | Health Care, Medical Device, Medical | $5.3M–$60M |
|
Lynx Capital
VC Fund
|
1 | Finland, United States | Series A, Venture - Series Unknown, Seed | Health Care, Medical, Biotechnology | |
|
Unifund
VC Fund
|
1 | Finland | Seed, Venture - Series Unknown | Medical, Software, Biopharma | |
|
Visionplus
VC Fund
|
1 | Finland, United States, United Kingdom | Seed, Venture - Series Unknown, Series A | Software, Information Technology, Internet | $83k–$14M |
|
DigiTx Partners
VC Fund
|
1 | United States, Canada, Finland | Series A, Seed, Series B | Health Care, Artificial Intelligence, Medical | $2.7M–$43M |
|
Noaber
VC Fund
|
1 | The Netherlands, Israel, Germany | Seed, Series A, Pre-Seed | Health Care, Medical, Fitness | $423k–$20M |
|
Inveni Capital
VC Fund
|
1 | Finland, United Kingdom | Venture - Series Unknown | Medical, Health Care, Biotechnology | |
| Access all 107 VC funds in Finland Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Business Finland finances business R&D projects and public research projects at universities, research institutes and universities of applied sciences. Read more about R&D and business funding.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Grant, Seed, Debt Financing
- Geography: Finland, United States, Sweden
Investor stats
- Total investments: 238
- Round size: Seed $334k–$3.5M; Grant $50k–$10M; Debt Financing $252k–$6.5M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- STRGY AI — The strategy was never the problem. The evidence was correct, sitting in someone's hands, and it died anyway because nothing in the organization was built to carry that evidence from where it was seen to where it could be acted on, and keep it alive long enough to matter. Not a bad plan. Not bad people. A structural gap between signal andauthority that every existing tool — decks, dashboards, status meetings — is too static and too easy to ignore to actually close.STRGY exists because that gap is the default state of every organization above a certain size, and closing it has always required either a heroic individual repeating themselves for years or luck (the corporate pilot needed one person to remember "do not drop this" at the right moment, and no one did). That's not a strategy problem to solve with a better framework — it's an infrastructure problem. You need something that holds the signal, doesn't forget it, doesn't get bored repeating it, and resurfaces it automatically the moment the gap between evidence and action starts to widen. That's what a human can't do reliably at scale, and what software with real memory can.
- Coolbrook — Our RotoDynamic electric technology can cut 30% of industrial emissions annually, delivering hope at industrial scale.
- Solar Foods — Solar Foods is a food-tech startup that specializes in testing a technology that uses electricity to produce hydrogen which is combined with carbon dioxide, water, vitamins, and minerals to feed and grow microbial biomass that can be used as edible protein. The industrial biotech startup develops a protein called Solein, a nutritious, sustainablesubstitute for animal-derived proteins. Solein is created using elements from the air—CO2, water, nitrogen—and electricity. This single-cell protein is cultivated through gas fermentation, essentially deriving edible calories from hydrogen-oxidizing microbes.
Finnvera makes direct investments in early-stage enterprises through Seed Fund Vera Ltd. Finnvera's goal is to cover shortcomings existing on the market between product development funding and private equity investments. Finnvera does not compete with private financiers; instead, it strives to supplement the financial market.Finnvera'sinvestments enable, start and accelerate growth and internationalisation among investment targets. Enterprises are developed to make them attractive targets for further financing by other investors and industrial actors. Investments are made in technology enterprises at an early stage and in technology-intensive or innovative service enterprises that have potential for developing into international growth enterprises.Finnvera is also known as a specialised financing company owned by the State of Finland. It provides its clients with loans, guarantees, venture capital investments and export credit guarantees.
Show more...Investment focus
- Industry: Software, Health Care, Manufacturing
- Stage:Seed, Series A
- Geography: Finland, United States, Chile
Investor stats
- Total investments: 95
- Round size: Seed $250k–$2.3M; Series A $1.8M–$23M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- ARAUCO — ARAUCO is a diversified global company in the forestry industry. They use world-class technologies and processes throughout the value chain. They are present in the forestry, pulp, timber, panels and renewable energy businesses.
- eMabler — EMabler is an EV charging infrastructure software company that develops an API-first platform used by businesses to operate, manage, and scale electric vehicle charging networks. It provides a centralized system for charge point management, billing, pricing, roaming, and energy optimization, allowing operators to control large networks of EVchargers from a single platform. The software connects charging hardware with business systems such as CRM, payment, and energy management tools through open APIs and a large library of integrations. The company focuses on enabling enterprises, such as energy utilities, parking operators, and retail businesses, to embed EV charging directly into their existing services and digital platforms rather than building standalone charging systems. This includes white-label solutions where charging is integrated into a company’s own app or customer experience under its brand.
- CHAOS — At CHAOS, we strive to democratize data and harness the power of AI and cutting-edge technology, delivering transformative location insights that empower decision-makers to design more liveable cities- sustainable, human-centered where the quality-of-life soars.
Lifeline Ventures Oy is a venture capital firm specializing in startups, growth capital, and early stage investments. The firm seeks to invest in healthcare, games, web based and general high technology sectors. It seeks to invest in Finland with a few investments made outside Finland as well. The firm targets investing between €0.5 million ($0.66million) and €1 million ($1.32 million). It seeks make inception to Series A investments. Lifeline Ventures Oy was founded in November 2009 and is based in Helsinki, Finland.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Finland, United States, United Kingdom
Investor stats
- Total investments: 203
- Round size: Seed $580k–$5.4M; Series A $2.8M–$22M; Venture - Series Unknown $430k–$17M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $464M in 2025
Portfolio highlights
- Verda — Verda provides a full-stack AI cloud platform for the development, training, and deployment of AI models.
- S-Transistors — S-Transistors is one of the few businesses founded on a truly novel core technology that has the potential to serve as an enabling layer for a whole industry.
- Thor Dynamics — Directed Energy Systems for Counter-Drone Defense
Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Sweden, Norway
Investor stats
- Total investments: 61
- Round size: Seed $1M–$5.9M; Pre-Seed $464k–$2.1M; Series A $3.9M–$30M
- Lead/follow: 64% lead, 36% follow
- Last fund: Likely still investing — raised $108M in 2023
Portfolio highlights
- Reduciner — Reduciner's vision to turn industrial CO₂ emissions from a liability into a valuable resource. Its technology converts captured carbon dioxide and biochar into valuable feedstocks such as carbon monoxide and activated carbon, enabling circular carbon use in emissions-intensive industries. Reduciner combines strong scientific expertise withindustrial applicability across sectors such as cement, steel, and chemicals. Its electricity-driven process allows industries to reduce emissions without major changes to existing infrastructure, offering a resilient and cost-competitive way to reduce carbon dependency while creating new value from CO₂ emissions.
- TheStorage — Flexible industrial heat electrification and scalable energy storage. TheStorage offers cost efficient, sustainable grid scale energy storage that can discharge heat, steam or CHP.
- Photoncycle — The year-round solar energy system for heating and electricity
Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: Finland, Sweden, Denmark
Investor stats
- Total investments: 97
- Round size: Seed $477k–$4.5M; Pre-Seed $204k–$2M; Venture - Series Unknown $529k–$5.1M
- Lead/follow: 56% lead, 44% follow
- Last fund: Likely still investing — raised $33M in 2023
Portfolio highlights
- Khoy — Khoy Company designs and develops comfortable, user-friendly, and sustainable sofa beds.
- AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
- Bahn Express — Bahn Express is a global car transportation company that supports independent contractors while offering quick and easy auto shipping throughout Europe.
Founded in 2016, Icebreaker has invested in over 50 fast-growing tech startups built by domain expert founders from companies like Rovio, Nordea, Pipedrive, Eniram, IBM and BCG. In addition to the fund, Icebreaker also runs a community of more than 1000 founders and pre-founders with 5+ years of relevant industry experience and the will to start,build or join strong tech companies.With the initial ticket sizes of €150k - 800K Icebreaker provides enough funding for companies to get to a position of strength and avoid post-accelerator limbo without having to resort to disreputable sources of capital and unfriendly deal terms.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Pre-Seed, Seed, Series A
- Geography: Finland, Sweden, Estonia
Investor stats
- Total investments: 143
- Round size: Seed $409k–$5.4M; Pre-Seed $110k–$1.3M; Series A $3.1M–$25M
- Lead/follow: 56% lead, 44% follow
- Last fund: May invest from a new fund soon — raised $24M in 2021
Portfolio highlights
- Cytely — Cytely operationalizes biological measurement, turning microscopy into standardized, reproducible data so research teams can accelerate discovery.
- Oplane — Connect your repo. See and fix your vulnerabilities in minutes. AI-powered threat modeling - no consultants, no weeks of docs.
- Cota Robotics — Cota Robotics deploys general-purpose robots in retail stores through a Robot-as-a-Service model, integrating with existing environments without requiring changes to store layouts or infrastructure. The company automates shelf replenishment, inbound handling, and order picking using human-in-the-loop teleoperation, with autonomy increasing asdeployment data trains its models.
We partner with deep tech and brand-driven companies obsessed in challenging category norms. The Nordics are our home, but we take on a global front in spotting the unexpected - from B2B to B2C, with a sweet spot for scientific advances, strong IP, and customer understanding that looks beyond convention.We invest in early stage companies: fromtheir inception to series A and beyond. We share in the vision of founders as champions and challengers, drawing on our experiences from scaling some of the strongest tech companies ourselves.
Show more...Investment focus
- Industry: Software, E-Commerce, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Finland, Norway, Denmark
Investor stats
- Total investments: 103
- Round size: Seed $948k–$8.3M; Pre-Seed $578k–$2.7M; Series A $3.5M–$37M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $106M in 2024
Portfolio highlights
- Aavuus — Aavuus is building a global network of ground-based laser stations to detect and track space debris with high precision.
- Metaktik — Tactical Metasurface Antenna Solution for Defence. Ultralight Antennas for Satellites.
- Quanscient — Quanscient develops multiphysics simulation software utilizing quantum computing algorithms to improve simulation technology. Its Computer Aided Engineering (CAE) platform integrates a unique combination of cloud-native multiphysics solvers, advanced cloud computing, and future quantum integration. The platform also offers engineers over ahundredfold increase in simulation throughput to enable fully digital R&D processes, addressing complex technology challenges in industries like fusion energy, 6G/7G, advanced semiconductors, biomedical, automotive, and aerospace.
Butterfly Ventures is a seed-stage focused VC in the Nordics, investing in deep tech, hardware, and hardware interfacing software. The company prefers to get involved with companies early on; 80% of Butterfly Ventures portfolio companies don't have any revenue at the time of their entry. Butterfly Ventures was founded in 2012 and ever sincethen it has been one of the most active early stage VCs in the region. The company has offices in Oulu, Helsinki and Stockholm.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Finland, Sweden, Norway
Investor stats
- Total investments: 91
- Round size: Seed $224k–$2.2M; Pre-Seed $110k–$4.3M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $49M in 2022
Portfolio highlights
- DREV — DREV is a cleantech company manufacturing contamination control solutions for the world’s most advanced manufacturing facilities.
- Zenniz — Zenniz is an ITF approved game tracking solution that provides real-time info, such as automated line calling, stroke and serve speeds, shot charts, match statistics and more. Players and coaches at all levels can use Zenniz on and off the court to help improve their game. For tennis clubs, Zenniz is an easy and cost-effective way to upgrade to thenext level. Due to a new, innovative sensor technology, they’ve been able to keep the cost to a minimum, making Zenniz accessible for all clubs, coaches and players.
- Polar Light Technologies — Polar Light Technologies focuses on developing the next generation of Nano and micro LED technology.
Organizing and investing in a global army of entrepreneurs committed to achieving health moonshots
Show more...Investment focus
- Industry: Health Care, Medical, Wellness
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 361
- Round size: Seed $100k–$4M; Pre-Seed $20k–$854k; Venture - Series Unknown $150k–$15M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $31M in 2018
Portfolio highlights
- AvoMD — AvoMD is reimagining clinical decision support with interactive point-of-care software, available standalone and via EHR integrations, and seamless content building tools.
- Hidoc Consult — Hidoc Consult: Boost your well-being with free consultations, 24/7 access to quality healthcare, complete privacy, user-friendly, and a trusted network of HCPs
- NEXT Life Sciences — NEXT Life Sciences is developing the revolutionary Plan A™ procedure to bring the only scientifically proven technology in the category - Vasalgel® - to market.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 407
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Venture - Series Unknown, Seed
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 32
- Round size: Venture - Series Unknown $3.2M–$10M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- BOOST Pharma — BOOST Pharma is developing BT-101, an off-the-shelf therapy for early intervention in children with severe osteogenesis imperfecta (OI).
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
- Umecrine Cognition — Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 188
- Round size: Seed $2.4M–$24M; Series A $5.8M–$50M; Series B $13M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 234
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.
We partner with founders to transform unseen scientific discoveries into future breakthroughs, jointly moving businesses, people, and the world forward.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Diagnostics
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Sweden, United States
Investor stats
- Total investments: 18
- Round size: Seed $373k–$4.6M; Pre-Seed $380k–$837k; Series A $2.9M–$34M
- Lead/follow: 83% lead, 17% follow
- Last fund: Likely still investing — raised $34M in 2024
Portfolio highlights
- CubaseBio — Cubase Bio is a biotechnology business that focuses on spatial biology tools. It creates solutions for 3D spatial analysis to speed up drug discovery.
- mu-ray.tech — MuRay Tech generates a controlled muon beam to image inside solid metal and 3D printed pieces. Non-destructively. In minutes.
- Kasvu Therapeutics — Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered
Reaktor Ventures they invest in seed stage companies and helps them to create markets.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Germany, United States
Investor stats
- Total investments: 60
- Round size: Seed $137k–$2.1M; Pre-Seed $158k–$1.8M; Series A $1.7M–$6.8M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Valpas — Valpas is the hygiene protocol that reassures your future guests and keeps your hotel clean from the most uncontrollable: bed bugs
- allies.digital — Allies is a match-making platform curating businesses with IT-, digital and creative agencies. No more miss-matches when buying IT & creative services.
- StarBerry Games — StarBerry Games GmbH is a mobile games company based in Berlin, Germany. The company develops free-to-play casual mobile games and is best known for its games Merge Mayor and Idle Coffee Corp.
The Citizenship Fund started out when the founders of the company discovered in their previous positions that a promising Finnish growth company will spend a great deal of time and energy in arranging financing. A good business idea and a team with excellent team could take months in financial negotiations and the outcome could be a return to thestart-up. At the same time, investors often wanted new types of higher potential investments alongside traditional alternatives.These two challenges were possible by removing the promising growth companies as investors, even for non-traditional venture capital investors. Citizenship wanted to create a service in which the company would be able to capitalize on business quickly and flexibly, but the decision-making business would be left to the company itself. From today's point of view, Springvest's goal is that an increasing number of Finnish investors can get involved in the story of Finnish growth companies and potential success.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: Finland
Investor stats
- Total investments: 23
- Round size: Seed $1.6M–$7.6M; Series A $3.6M–$53M; Venture - Series Unknown $4.7M–$29M
- Lead/follow: 74% lead, 26% follow
Portfolio highlights
- ReOrbit — Looking for a way to keep your data flowing in space? ReOrbit has you covered with our line of autonomous and inter-networking satellites!
- MedicubeX — MedicubeX aims to revolutionize preventive healthcare by building a network of autonomous self-measurement and telehealth eHealth Stations. We are the most advanced health kiosk and the first one in the Nordics. The eHealth Station offers regular clinical-grade medical check-ups for everyone regardless of location.
- CurifyLabs — CurifyLabs enables 3D printed personalized medicines in pharmacies and hospitals. Always close to the patient.
Finnish Industry Investment Ltd is a government-owned investment company. It invests the proceeds accrued from the privatisation of state-owned companies in stimulating the growth and internationalisation of Finnish businesses.Finnish Industry Investment invests in venture capital funds and directly in growth companies, together with privateco-investors. The targets are in all sectors. Capital investments are needed for financing the growth of investee companies, and for spin-offs, major industrial investments, and sector and corporate restructurings.The investments of Finnish Industry Investment amount to over MEUR 570
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Series B
- Geography: Finland, United States, Switzerland
Investor stats
- Total investments: 154
- Round size: Series A $2.4M–$46M; Series B $3.1M–$40M
- Lead/follow: 16% lead, 84% follow
- Last fund: May invest from a new fund soon — raised $177M in 2017
Portfolio highlights
- Vexlum — A #laser company providing high-power #VECSELs for #QuantumTechnology
- Verda — Verda provides a full-stack AI cloud platform for the development, training, and deployment of AI models.
- Kasvu Therapeutics — Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered
We are Sandwater. Regeneration of our resources. Vitalizing healthcare & education. Improving life through technology.
Show more...Investment focus
- Industry: Manufacturing, Medical, AgTech
- Stage:Series A, Venture - Series Unknown, Series B
- Geography: Norway, Germany, Finland
Investor stats
- Total investments: 24
- Round size: Series A $8.5M–$24M; Series B $17M–$35M; Venture - Series Unknown $4.7M–$18M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Mantle8 — Using bottom-up exploration and decades of geology experience, we are on a mission to deliver natural hydrogen to the world.
- CurifyLabs — CurifyLabs enables 3D printed personalized medicines in pharmacies and hospitals. Always close to the patient.
- Alva Industries — Serving industries from aerospace to marine, we deliver high-performance, sustainable motors to drive a cleaner, more efficient future.
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Belgium, Germany, France
Investor stats
- Total investments: 61
- Round size: Series A $3.9M–$20M; Series B $4.4M–$26M; Series C $7.8M–$100M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $103M in 2023
Portfolio highlights
- Nutrium — Nutrium is the most up-to-date nutrition software for dietitians and nutritionists to manage their nutrition business with nutritional assessment, meal planning and progress tracking.
- ENYO Pharma — ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Nuard Ventures invests in innovative early stage companies.
Show more...Investment focus
- Industry: IaaS, Video, Gaming
- Stage:Seed, Angel, Pre-Seed
- Geography: Finland, Germany, United States
Investor stats
- Total investments: 9
- Round size: Seed $159k–$680k
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- WARD — WARD is a fantasy sport game, where fans can watch their favourite eSports matches and predict what will happen in real time.WARD is a startup out of Berlin which has created a “pick and predict” real-time prediction smartphone game, where players can win real prizes. People love to watch e-sports. We believe on these occasions they still want tobe able to participate.However, until now no product has offered anything other than the ability to watch. There’s been no way for fans to spectate, participate, analyse and predict the outcomes of their favourite games.
- MVision AI — AI-powered solutions that automate repetitive tasks, enable efficient radiotherapy workflows, and promote consistency across clinical processes.
- Polka Dot Studio — Kalian Bisa Memasang Taruhan Online Dengan Sangat Mudah Dan Nyaman Di Situs DEWAHOKI Yang Sudah Resmi Di Indonesia
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Metsola Ventures
Show more...Investment focus
- Industry: Medical, mHealth, Automotive
- Stage:Series A, Pre-Seed
- Geography: Finland
Investor stats
- Total investments: 3
- Round size: Series A $2.2M–$5.4M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kaiku Health — Kaiku Health is a digital health company with a mission to improve quality of life through health data science. We have built an intelligent digital platform for monitoring patient-reported outcomes in several therapy areas, such as cancer care, fertility treatments and preventive health care. Its unique algorithms enable early interventions andpersonalized patient support. Currently over 30 European hospitals and clinics are using our platform to better monitor their patients, reducing manual work and allowing prioritization of clinical actions. This along with the capture and analysis of real-world data paves way for more personalized and effective care of each patient. The company, founded in 2012 by five software developers deeply passionate about health care technology, has now grown to team of 20+ dedicated employees. The company is backed by Reaktor Ventures, along with other venture capital funds and private investors, and is supported by Tekes – the Finnish Funding Agency for Innovation.
- RoadCloud — Use the worlds most accurate road condition data to your advantage. Real-time hyperlocal road weather data from your road network 24/7.
- Synoste — Globus Medical develops, manufactures, and distributes musculoskeletal device solutions. Learn about the implants and products we manufacture.
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: Finland, Sweden, United States
Investor stats
- Total investments: 180
- Round size: Seed $549k–$6M; Series A $1.3M–$17M; Series B $1.3M–$25M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $140M in 2022
Portfolio highlights
- Lassie — Lassie is the first proactive and preventive pet insurance company that wants to help pet owners take better care of their pets
- Capalo AI — We maximize the value of your energy storage systems. Now and in the future.
- Algorithmiq — Algorithmiq utilizes its expertise in quantum information, complex systems, and computational physics to develop algorithms to develop new and effective drugs, solve problems in life sciences, and discover new materials.
Samsung Venture Investment is plays the role of driving the discovery and development of new businesses and technologies.
Show more...Investment focus
- Industry: Information Technology, Artificial Intelligence, Software
- Stage:Series A, Series B, Seed
- Geography: South Korea, United States, India
Investor stats
- Total investments: 145
- Round size: Seed $83k–$4.1M; Series A $1.7M–$25M; Series B $2.8M–$23M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- MangoBoost — Data Processing Unit (DPU) is a next-generation server accelerator designed to orchestrate various intra-server devices (e.g., CPU, GPU, SSD, NPU, NIC). By maximizing the datacenter’s overall performance and cost efficiency, DPU is now considered as the most important HW/SW solution to realize the next-generation extreme-scale AI serverinfrastructure. However, despite its critical necessity from the datacenter and AI infrastructure, there is no market-leading DPU solution which can meet the customer’s actual demand due to its HW/SW complexity and the application/model heterogeneity. MangoBoost is currently the world’s most highly recognized DPU startup located in US and Korea. We provide the world’s most advanced and flexible DPU HW/SW solutions in order to fully satisfy the needs of various customers. Our DPU HW is fully composable by integrating its rich set of DPU features to construct our customer-optimal DPUs. At the same time, our DPU SW enables to seamlessly deploy the solution to any customer environment. As a result, our DPU solutions are considered very promising to realize the next-generation AI/datacenter infrastructure, and thus they are currently evaluated at various global-leading companies. MangoBoost was founded in early 2022 to commercialize 7 year of top-tier DPU research outcomes achieved at Seoul National University (e.g., many full-system DPU prototypes, many ISCA/MICRO/ASPLOS/OSDI/ATC papers). The current team consists of 45+ system engineers including ~20 top-tier PhDs from Carnegie Mellon University, Seoul National University, POSTECH, U Toronto, and ~20 industry experts from Intel, Microsoft, Samsung, and Naver.
- AIDIN ROBOTICS — AIDIN ROBOTICS redefine interactive sensors. Advanced force/torque sensor, proximity sensor for human-robot collaboration.
- Aim Intelligence — Leading AI Security & Safety Solutions Provider - Specializing in AI Risk Detection, Mitigation, and Elimination through Advanced Red Teaming and Defensive Systems | Leading provider of AI Security, Safety, and Compliance solutions
The University of Helsinki has the widest range of disciplines in Finland. It was established in Turku in 1640, but was transferred to Helsinki in 1828. The number of faculties is eleven. There are 35,000 degree students and 7,900 staff. The number of degrees taken each year is an average 5,000, of which about 470 are doctorates. The Universityconcentrates on high-level scientific research and researcher education. Scientific research is also the basis of the teaching provided by the University. The University operations support the development of society, as well as business and industry. University representatives offer their competencies for the benefit of society through a number of positions of trust and expertise. The results produced by the research and teaching carried out at the University have been widely acclaimed. The University participates in more than half of the national Centres of Excellence in Research, elected by international scientific panels. The University of Helsinki has been invited to be a member of the League of European Research Universities, a co-operation body for the leading European research universities. According to international expert panels, also the teaching provided by the University of Helsinki is of a high European level. The University has strong international connections. It has some 80 co-operation agreements with universities on different continents. The University researchers are in great demand as experts in international scientific communities, meetings and publications. The University is bilingual, but in addition to Finnish and Swedish teaching is also provided in English. Besides Helsinki, the University has operations at 20 localities throughout Finland.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: Finland, Luxembourg, United States
Investor stats
- Total investments: 12
- Round size: Seed $54k–$7.4M; Pre-Seed $837k–$1.2M; Series A $2.9M–$34M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Ferrivia — Ferrivia on suomalainen palvelu, joka keskittyy raudanpuutteen ja rautaterveyden mittaamiseen.
- Avenue Biosciences — From biotechnology tools to therapy discovery and development: Our platform enhances production yield and the quality of your end product.
- Kasvu Therapeutics — Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered
96 Normal 0 false false false EN-GB X-NONE X-NONE
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: Germany, Finland, The Netherlands
Investor stats
- Total investments: 13
- Round size: Series A $2M–$7.9M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Fiagon — Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation.
- Meidrix Biomedicals — Meidrix Biomedicals is a medical biotechnology company that specializes in medical devices for cartilage repair. Meidrix Biomedicals also offers regenerative and biological medical products. Meidrix Biomedicals was founded in 2009 and was headquartered in Bayern, Germany.
- SurgicEye — SurgicEye designs intra-operative imaging and instrument navigation solutions for surgical procedures. It offers a navigated radio-guided surgery based on the handheld 3-D freehand SPECT imaging technology called the declipse SPECT open surgery, an intraoperative 3D imaging system for invasive sentinel lymph node biopsy called the declipse SPECTLaparascopy, and a mobile SPECT imaging solution with a high resolution on a small footprint called the declipse SPECT imaging probe. The company also advises clients on medical device development, requirement engineering and software specification for medical devices, software development for medical devices, testing of software for medical devices, and support in the design and conduction of clinical studies.Dr. Jörg Traub founded SurgicEye in 2008, with its headquarters in Munich in Germany.
VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: Italy, United Kingdom, Switzerland
Investor stats
- Total investments: 48
- Round size: Series A $3.5M–$33M; Series B $8.9M–$89M; Series C $18M–$110M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $302M in 2018
Portfolio highlights
- Newcleo — newcleo is the clean and safe nuclear technology company. Privately funded and headquartered in London, UK, newcleo was launched in 2021 to be a disruptor in the field of nuclear energy. Its mission is to generate safe, clean and inexhaustible energy for the world, through a radically innovative combination of existing, accessible technologies.newcleo is building the next generation system with the goals to: (1) eliminate the need for geological repositories by using a fast neutron flux avoiding production of long life radioactive elements; (2) develop an Accelerator Driven System (ADS), based on the intrinsically safe coupling of a particle accelerator and a sub-critical reactor; (3) accelerate the development of new fuel cycles, including thorium, that provide economic, clean, safe and inexhaustible energy from nuclei and the opportunity to burn the long-lived nuclear waste produced by the old generation of nuclear reactors.With visionary co-founders, newcleo brings together a team of engineers with deep knowledge of nuclear energy with younger recruits with a fresh mindset, working to design an innovative micro Lead Fast Reactor with significant commercial applications, for example in shipping. newcleo wants to be the first step toward the evolution of its industry to become fully respectful of people and the environment. To develop a new, sustainable, and completely safe way of generating nuclear energy that will lead humanity to zero emissions, and to the mitigation of global warming.
- Easy Rain — Leading a new automotive era: our modular ecosystem of virtual sensors and active hardware makes cars and autonomous platforms truly safe in every condition.
- Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.
Korpun Siemen is backed by 33 investors who have combined their initial investment activities and have extensive experience in start-up, growth and family businesses in various industries. The company includes active angel investors, entrepreneurs in growth companies and investors who have already exited their companies.
Show more...Investment focus
- Industry: Software, Marketing, Information Technology
- Stage:Seed, Venture - Series Unknown, Angel
- Geography: Finland
Investor stats
- Total investments: 10
- Round size: Seed $480k–$1.3M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Mobal — It is time to get your Business Profiles in shape. Meet your customers where they are and stand out where it matters most.
- Remod — Remod provides holistic IT surveys, backup services, cyber control, functional programming, data processing, incident response, secure systems, network design, and proof of concept development.
- Builderhead — Builderhead is an easy-to-use construction management software that helps owners, developers and general contractors complete construction projects on time and within budget.
Lednil is an investment firm.
Show more...Investment focus
- Industry: Medical, Commercial, Health Care
- Stage:Series A
- Geography: Finland
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
an early-stage investment firm making long-term bets on contrarians and leveraging the knowledge and network across sectors. We back mission-driven founders working on positively disruptive deep technologies.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Estonia
Investor stats
- Total investments: 110
- Round size: Seed $1.7M–$12M; Series A $5.9M–$40M; Series B $23M–$62M
- Lead/follow: 13% lead, 87% follow
- Last fund: Likely actively investing — fresh fund, raised $69M in 2025
Portfolio highlights
- Kopra Bio — Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
- Inherent — Recursively self-improving to discover new knowledge.
- Lightyear — Lightyear is a simple and approachable way to invest your money globally without unnecessary barriers and fees.
Force 10 Partners is an advisory firm with deep domain knowledge in financial and operational corporate restructuring,
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed
- Geography: Finland
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- RNatives — RNatives specializes in the field of biotechnology, focusing on the development of innovative RNA-based therapies. The company's expertise lies in RNA activation, particularly targeting VEGFA for the treatment of cardiovascular diseases. RNatives is dedicated to advancing its lead programs through rigorous research and development, aiming tooffer novel therapeutic options for conditions with unmet medical needs. With a team of skilled professionals, RNatives is committed to pushing the boundaries of biotechnology to improve patient outcomes.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 81
- Round size: Series B $7M–$42M; Series C $12M–$45M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely actively investing — fresh fund, raised $10M in 2025
Portfolio highlights
- eZono — eZono is a young dynamic company focused on point of care solutions. Based in Jena, Germany, eZono brings together a multicultural team of experts, bringing a diverse and fresh approach to ultrasound guidance of interventional procedures.Founded in 2004, eZono AG is a different kind of ultrasound company, one that empowers non-traditionalultrasound users to incorporate sonography in their daily work. This enables their customers to improve clinical outcomes, enhance patient satisfaction and in particular lower cost. As a result they bring not only affordable portable sonography technology to specific applications but also makes it easy for instance for anesthetists to operate – reducing drastically their learning effort.
- VitalConnect — VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatientsettings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions.
- Beacon Endoscopic — Beacon Endoscopic (BE) is a Boston based medical device company innovating in existing interventional endoscopic procedures and developing next generation devices to change the paradigm of surgery
Cor Group management consulting firm serving Psychological, Educational, and Behavioral Services.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland
Investor stats
- Total investments: 6
- Round size: Seed $2.3M–$8.7M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Gosta Labs — Focus on care
- Adamant Health — Adamant Health’s unique technology to analyse Parkinson’s disease symptoms is based on over 15 years of academic research at the University of Eastern Finland. With the technology, clinicians have several days detailed visibility to the patient’s symptoms and is able to optimise the treatment accordingly. Pharma companies benefit from the objectiveand long-term RW data in their clinical and post market studies and can utilise it as complementary diagnostics tool for personalised medication.
- Nightingale Health — The most advanced health check for the health industry.
CDP Venture Capital Sgr - National Innovation Fund aims to make venture capital a cornerstone of the country's economic development and innovation, creating the conditions for an overall and sustainable growth of the venture capital ecosystem.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: Italy, United States, United Kingdom
Investor stats
- Total investments: 295
- Round size: Seed $483k–$7.7M; Series A $3.3M–$23M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $197M in 2021
Portfolio highlights
- Evja — Evja supports growers in optimizing the management and monitoring of irrigation, nutrition and protection of their crops through the use of OPI, the most advanced system for precision agriculture .
- Mopso — Discover Mopso's anti money laundering detection system. Visit our website and try a 30 minutes free demo with one of our experts.
- ALLSIDES — Covision Media specializes in creating high-quality, relightable 3D models using their industrial 3D scanners. These scanners capture detailed surface information and PBR textures, and are designed for easy integration into virtual environments.
We are the home for entrepreneurs with a big vision who want to create something less ordinary. Something that matters. For all of us.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A, Series B
- Geography: Germany, United Kingdom, Finland
Investor stats
- Total investments: 73
- Round size: Seed $1.6M–$18M; Series A $3.9M–$17M; Series B $7.3M–$53M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fresh fund, raised $85M in 2026
Portfolio highlights
- Aitiologic — A precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy.
- Decade Energy — Decade Energy is the energy infrastructure and optimization partner for transport operators and depot managers who want to electrify their fleets.
- Entelo Bio — Precision Medicine
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Private Equity, Series B
- Geography: France, United States, Belgium
Investor stats
- Total investments: 57
- Round size: Series A $5.7M–$23M; Series B $7.2M–$48M; Private Equity $23M–$150M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
- Ceva Santé Animale — Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
- CorFlow Therapeutics — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 121
- Round size: Series A $3.3M–$18M; Series B $5.3M–$45M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $53M in 2025
Portfolio highlights
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
- Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
- Trillium Renewable Chemicals — Trillium Renewable Chemicals manufactures chemicals from renewable feedstocks used in a variety of industrially important applications. The company was founded in 2021 and based in Knoxville, Tennessee.
ZEISS Ventures is a cooperate venture arm of the ZEISS Group.
Show more...Investment focus
- Industry: Health Care, Semiconductor, Medical Device
- Stage:Series A
- Geography: Germany, United Kingdom
Investor stats
- Total investments: 10
- Round size: Series A $5.2M–$23M
- Lead/follow: 80% lead, 20% follow
Portfolio highlights
- Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
- Hypervision Surgical — Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging.
- SeeTrue Technologies — Ultra-low-power eye tracking from SeeTrue delivers accurate gaze data for AR/VR, microscope & camera eyepieces and wearables, powered by custom sensors.
Athensmed Oy
Show more...Investment focus
- Industry: Health Care, Health Diagnostics, Medical
- Stage:Seed, Series A
- Geography: Finland, Switzerland
Investor stats
- Total investments: 5
- Round size: Seed $1.1M–$4.3M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Biospectal — Measure and track blood pressure with only your phone camera and fingertip. With OptIBP, you can keep a diary of blood pressure, share BP, and take control of your heart health.
- Finnadvance — Finnadvance is an Organ-On-Chip company developing high throughput biological barriers on chips to mimic human biology such as vascular, lung and the Blood-Brain-Barriers for small molecule, micro-nano-formulation permeability and toxicity testing with in-vivo like dynamic cell cultures.
- Moncyte Health — Unique technology and novel data for personalized and optimal treatment of high cholesterol
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: Sweden, Norway, Austria
Investor stats
- Total investments: 36
- Round size: Series A $4.2M–$79M; Series B $4.5M–$75M; Venture - Series Unknown $2M–$29M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely still investing — raised $168M in 2021
Portfolio highlights
- Oncoinvent — Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns.
- Kasvu Therapeutics — Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Debiopharm invests in Smart Data & Digital Health companies developing technologies that are applicable in the areas of oncology or infectious diseases
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Seed, Pre-Seed
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 48
- Round size: Seed $943k–$6M; Pre-Seed $317k–$1.7M; Series A $3.5M–$25M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Octozi — AI agents that accelerate clinical development. Automate data cleaning, review, reconciliation, and reporting across your trials.
- ModernVivo — Search millions of preclinical papers and extract experimental conditions in minutes. Design faster, better-powered in vivo studies with deterministic results.
- MedaSystems — Streamline patient and provider inquiries for Expanded Access or Compassionate Use with secure, 21st Century Cures Act compliant, cloud software.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Nordea Bank is Denmark's second-largest bank and counts every fourth Dane among its customers. Through their nationwide network of some 340 branch offices and a broad range of self-service facilities, they are able to offer you a full scale of financial products and services, including Netbank, Online Investment, telephone banking and cashdispensers.
Show more...Investment focus
- Industry: FinTech, Financial Services, Banking
- Stage:Debt Financing, Seed
- Geography: Finland, Sweden, Norway
Investor stats
- Total investments: 23
- Lead/follow: no public data
Portfolio highlights
- Tibber — Tibber is a digital electricity supplier that offers smart solutions to minimize their customers’ consumption and costs. Its vision is to make sustainable energy consumption simple and affordable for all households. Tibber's mission is to reduce the residential electricity consumption for European households by 20 %. Founded in Norway andSweden in 2016, the company has expanded its offer to Sweden and Germany where it powers hundreds of thousands of homes. Tibber replaces traditional utilities with smart technology, supplying its customers with renewable energy at fair and transparent prices. In addition, its app provides real-time analytics into energy usage, and pairs with a variety of smart home devices to reduce electricity consumption at home. The company sells tech-gadgets in their online store and recently was licensed to balance the main power grid in Sweden with EVs.
- Statzon — Make data-driven plans & faster decisions with a simple access to +1M datasets & market reports about 8,000 topics from +200 trusted data providers.
- Get It Done Now — GIDN is a Nigerian Fintech Company targeting medium and low income population for Loans and Financial products. GIDN has in addition a cashless, mobile based community marketplace, with more than 5k members, and aims to regulate the informal economy and facilitate the purchase of Services and Digital Products.
Torrey Pines Investment, founded in 2002, is a specialty life-science investment company located in San Diego.Torrey Pines has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has created biopharma incubators investing in early development stage assets from internationalpharma and biotech partners in CNS, oncology, and virology areas to bring them to commercial success through pharma partnering and M&A.We are committed to capitalizing on the unique opportunities in biotech and pharma, where we can add value in development or regulatory strategy by utilizing resources of our portfolio CRO companies. We seek to leverage our industry knowledge, network of industry and financial contacts, and internal resources to assist our portfolio management in developing and executing their business strategy. Our bottom line is to help our companies achieve growth, build value and realize wealth.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Pre-Seed
- Geography: United States, Russian Federation, The Netherlands
Investor stats
- Total investments: 33
- Round size: Seed $3M–$3.1M
- Lead/follow: 18% lead, 82% follow
- Last fund: May invest from a new fund soon — raised $60M in 2017
Portfolio highlights
- Mondego Bio — Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.
- BIMINI Biotech — BIMINI Biotech is a startup that develops innovative therapeutic strategies for oncology. It is developing therapeutic strategies that target the growth hormone receptor (GHR) and its interaction with insulin-like growth factor 1 (IGF-1) for oncology, metabolic diseases, and aging.The company was founded in 2019 and is based in Leiden, TheNetherlands.
- Mair Therapeutics — Mair Therapeutics main goal is finding and creating a small-molecule ion channel activator to treat Parkinson's disease, a preclinical drug discovery business.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 63
- Round size: Series A $5.5M–$61M; Series B $9.5M–$58M
- Lead/follow: 16% lead, 84% follow
- Last fund: May invest from a new fund soon — raised $92M in 2019
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
SHS is an independent private equity company. Their focus is on investments in the MedTech, Life Sciences, Diagnostics, and Digital Health sectors.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Venture - Series Unknown, Series B
- Geography: Germany, Switzerland, France
Investor stats
- Total investments: 44
- Round size: Series B $5.3M–$60M; Venture - Series Unknown $6.6M–$21M
- Lead/follow: 57% lead, 43% follow
- Last fund: Likely still investing — raised $273M in 2022
Portfolio highlights
- Arzneimittelwerk Warngau — Unsere Schwerpunkte Karriere bei AMW
- ROTOP — ROTOP is a pharmaceutical company. They manufacture cGMP-compliant radiopharmaceuticals for diagnostics and therapy in the fields of nuclear medicine. They provide API/precursor synthesis, analysis kit development, project management, full regulatory support spect, PET, quality control, and therapy services. Their customers contact throughemail and phone number.
- Salvia BioElectronics — Our mission is to give people with migraine a better life. As a pioneer in the field of medical devices, Salvia BioElectronics is passionately committed to empowering people with migraine to reclaim their lives.
cross-border, healthcare, life science, investment, VC, China, US
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: Finland, United States
Investor stats
- Total investments: 5
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Marginum — Pioneering the next-generation quantitative surgical techniques.
- Elucida Oncology — Elucida Oncology focuses on transforming outcomes for patients with primary solid tumors and metastatic cancer. The company utilizes the novel target or clear capabilities of its ultra-small C-Dot cancer-targeting particle platform across diagnostic imaging, surgical, and a wide range of therapeutic applications.
- Bone Index Finland — Bindex® is – in addition to DXA devices – the only device that can be used for osteoporosis diagnostics with international guidelines (ISCD) and the Finnish Current Care Guidelines (04/2014).Bindex® is applied by measuring the cortical thickness of tibia. The results, combined with other patient data, are used to estimate the hip region’sbone mineral density. Bone mineral density values (g/cm2) are normally only received via the large DXA devices used in hospitals.Bindex®’s quickness and simplicity make its use possible in high volume risk group screenings. It makes the identification of an osteoporosis risk possible before the first bone fracture has even occurred. Thus, it both improves the patient’s quality of life and saves on public health care expenses.
Unifund Jyväskylä Ltd is to support the start-up of research-based businesses.
Show more...Investment focus
- Industry: Medical, Software, Biopharma
- Stage:Seed, Venture - Series Unknown
- Geography: Finland
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Humap — Howspace is an AI-powered online platform that brings digital collaboration and social learning to the forefront of your process & development initiatives.
- PrecisionPhage — PrecisionPhage Ltd. is a Finland-based biotech company specialized in bacteriophage technologies. Join Phagenomics: https://t.co/R9NxBAecv5
WE HELP YOU TO GROW FASTER!
Show more...Investment focus
- Industry: Software, Information Technology, Internet
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Finland, United States, United Kingdom
Investor stats
- Total investments: 75
- Round size: Seed $83k–$1.3M; Series A $2M–$14M; Venture - Series Unknown $100k–$4M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- SingOn — SingOn is an on-demand karaoke service for PlayStation 3. It aims to modernize singing games by developing a clean and modern interface design. SingOn’s dynamic streaming services allow its developers to launch with thousands of songs and to update the game every week with new tracks.SingOn provides its users with a wide variety of songs and isconstantly updated with more songs, including songs from the UK Top 20 Charts. It was launched in 2009 by Risto Valkola and Samu Keränen.
- LiveMusicStage — We're a live music venue online. We let you to actually take part in the shows and interact with the bands while they're playing. You're always in the front row
- Logonet promotion — Logonet was established in 1992 in Finland and has since grown to a company with offices in nine countries and three continents.
At DigiTx Partners,we believe that the pace of change in healthcare will only accelerate in the coming years. We believe that there are many smart people with great insights and drive who are developing innovative technologies and solutions. We look forward to supporting innovative companies that will make a difference in our healthcareecosystem, from companies that will change how patients navigate the healthcare system, that will integrate the disparate elements that comprise both diagnosis and treatment, that will speed the development of more effective drugs and that will enhance and enable efficient and accurate physician-patient interaction. DigiTx Partners looks forward to investing in those digital health companies that strive to keep all of us in better health.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Medical
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Finland
Investor stats
- Total investments: 32
- Round size: Seed $2.7M–$7.8M; Series A $5M–$23M; Series B $6M–$43M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $75M in 2018
Portfolio highlights
- Neon Health — Neon accelerates patient access to critical care by jumping through all the hoops to onboard and adhere to life-saving drugs, treatments.
- Biobase — Biobase is the agentic system for clinical data, closing the gap between clinical data and better healthcare.
- Auxira Health — Virtual APP-led care pods for cardiology. One APP, one MA and a fractional RN work in your EHR, clear the inbox and handle routine follow-up visits.
Noaber Ventures invests in initiatives that bring social transformations using information technology.
Show more...Investment focus
- Industry: Health Care, Medical, Fitness
- Stage:Seed, Series A, Pre-Seed
- Geography: The Netherlands, Israel, Germany
Investor stats
- Total investments: 20
- Round size: Seed $423k–$6.3M; Series A $3M–$20M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Plasmacure — Plasmacure develops innovative plasma technology for wound care. Discover how cold plasma is transforming the treatment of chronic wounds.
- Mirantus Health — Mirantus is building a distributed healthcare provider to improve access to care for underserved patients. Through healthcare services (Mirantus Care) and cloud-solutions (Mirantus OS), Mirantus empowers doctors to efficiently treat patients who were difficult to reach before. This improves healthcare access for patients, allows physicians to earnmore, while saving payors billions in downstream costs. Mirantus is on a mission to get every specialist physician in Europe to participate in distributed healthcare, to improve healthcare access for 100M+ underserved patients.
- Alba Health — Discover your baby's gut health & microbiome for the best start in life.
Inveni Capital is a venture capital management company focused on investments in early to growth stage life sciences companies.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Venture - Series Unknown
- Geography: Finland, United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- BioSilta — BioSilta Ltd. is a privately-held company that utilizes its unique, proprietary EnBase® technology platform to develop innovative, reagent-based EnPresso® growth systems. When compared to conventional growth media, EnPresso growth systems significantly increase the yield of high quality biomolecules from microbial cultures.
- Onbone — Woodcast uudetkasinot esittelee ajankohtaiset ja huolellisesti valitut uudet nettikasinot, tarjoten suomalaisille pelaajille tuoreita pelimahdollisuuksia, innovatiivisia ominaisuuksia ja luotettavan pelikokemuksen.
Medical VC funding in Finland at a glance
Stats across 127 deals from 107 investors.
Access all 107 VC funds in Finland Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical VC Funds in Finland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 107 VC funds investing in Finland Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!